Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Alligator Bioscience AB ( (SE:ATORX) ).
Alligator Bioscience announced that data from its Phase 1 REACtiVe-2 trial will be presented at the ESMO Congress 2025, highlighting the immune activation effects of mitazalimab in combination with dendritic cell therapy for metastatic pancreatic cancer. The trial results demonstrated safety and enhanced immune responses, with half of the patients achieving stable disease and increased tumor-infiltrating T cells, reinforcing mitazalimab’s potential in novel immuno-oncology therapies.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company based in Lund, Sweden, specializing in the development of clinical-stage tumor-directed antibody drugs. The company focuses on the CD40 receptor, an immuno-oncology approach that enhances T cell priming and counteracts the immunosuppressive tumor microenvironment. Alligator’s lead drug candidate, mitazalimab, is advancing towards Phase 3 development and has shown promising results in treating metastatic pancreatic cancer.
YTD Price Performance: -80.12%
Average Trading Volume: 497,669
Technical Sentiment Signal: Sell
Current Market Cap: SEK183.4M
See more insights into ATORX stock on TipRanks’ Stock Analysis page.